Home/Biosimilar Atlas/Companies/Merck Sharp & Dohme

Merck Sharp & Dohme

Biosimilar developer, United States. 1 development product across 1 molecule: insulin glargine.

FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Connections
1molecule1product0 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin glargineLusduna·withdrawn·····0/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Merck Sharp & Dohme, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsOne shared molecule: insulin glargine9 molecules in its portfolioCiplaOne shared molecule: insulin glargine1 molecule in its portfolioEli LillyOne shared molecule: insulin glargine1 molecule in its portfolioEris LifesciencesOne shared molecule: insulin glargine2 molecules in its portfolioGan & Lee PharmaceuticalsOne shared molecule: insulin glargine3 molecules in its portfolioGenesys BiologicsOne shared molecule: insulin glargine1 molecule in its portfolio

Chronology

Compare Merck Sharp & Dohme with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.